Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria

  title={Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria},
  author={Bruno Dubois and Howard H Feldman and Claudia Jacova and Harald Hampel and Jos{\'e} Lu{\'i}s Molinuevo and Kaj Blennow and Steven T. DeKosky and Serge Gauthier and Dennis J. Selkoe and Randall J. Bateman and Stefano F. Cappa and Sebastian J. Crutch and Sebastiaan Engelborghs and Giovanni Battista Frisoni and Nick C Fox and Douglas R. Galasko and Marie-Odile Habert and Gregory A. Jicha and Agneta Nordberg and Florence Pasquier and Gil D. Rabinovici and Philippe H. Robert and Christopher C. Rowe and Stephen P. Salloway and Marie Sarazin and St{\'e}phane Epelbaum and Leonardo Cruz de Souza and Bruno Vellas and Pieter Jelle Visser and Lon S Schneider and Yaakov Stern and Philip Scheltens and Jeffrey L. Cummings},
  journal={The Lancet Neurology},

Application of the IWG-2 Diagnostic Criteria for Alzheimer's Disease to the ADNI.

A large proportion of AD dementia subjects were categorized as typical AD, and the revised criteria could identify typical AD from MCI status as well as asymPTomatic AD at the asymptomatic stage, which supported the new biomarkers categorization in the refined criteria.

Biomarkers for the Diagnosis of Alzheimer’s Disease in Clinical Practice: The Role of CSF Biomarkers during the Evolution of Diagnostic Criteria

Technological advancement and expert recommendations may contribute to a more widespread use of these diagnostic tests in clinical practice to support a diagnosis of mild cognitive impairment (MCI) or dementia due to AD.

The Clinical Use of Alzheimer's Disease Biomarkers in Patients with Mild Cognitive Impairment: A European Alzheimer's Disease Consortium Survey.

Overall, it is observed that CSF is currently considered as the most useful biomarker, followed by amyloid-PET, which is widely used across European memory clinics with a clinical research background for the diagnosis of MCI.

A New Biological Definition of Alzheimer’s Disease: Introduction of 2018 National Institute on Aging-Alzheimer’s Association Research Framework

This review focused on the introduction of the new 2018 NIA-AA Research Framework, a biomarker-based classification combined with clinical staging that is expected to enhance the understanding of AD as well as aid in precise targeting for interventional clinical trials.

Are the revised diagnostic criteria for Alzheimer’s disease useful in low- and middle-income countries?

Alzheimer’s Disease is a leading cause of disease burden among elderly individuals that is increasingly important in middle-income countries like China where improvements in overall health and other factors are leading to a rapidly aging population.

Alzheimer's Disease Diagnosis Relies on a Twofold Clinical-Biological Algorithm: Three Memory Clinic Case Reports.

The case reports highlight that the isolated occurrence of one of the two proposed AD criteria, ASHT or positive pathophysiological markers, does not provide a reliable diagnosis of typical AD and it is proposed that the twofold diagnostic IWG algorithm can be applied and operationalized in memory clinic settings to improve the diagnostic accuracy of typical amnesic AD in clinical practice.

NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease

Cerebrospinal fluid biomarkers in Alzheimer's and Parkinson's diseases—From pathophysiology to clinical practice

This review provides an update on the role, development, and validation of CSF biomarkers in the diagnosis and prognosis of Alzheimer's disease and PD. Some recent developments on novel biomarkers



Application of the National Institute on Aging–Alzheimer’s Association AD criteria to ADNI

Objective: We describe the operationalization of the National Institute on Aging–Alzheimer’s Association (NIA-AA) workgroup diagnostic guidelines pertaining to Alzheimer disease (AD) dementia in a

New Research Criteria for the Diagnosis of Alzheimer’s Disease Applied in a Memory Clinic Population

The newly proposed research criteria for AD yield a good specificity for comparison with nondemented subjects, however, at least two supportive features should be considered when the type of dementia is clinically doubted.

Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

Clinical criteria for the diagnosis of Alzheimer’s disease include insidious onset and progressive impairment of memory and other cognitive functions, and Alterations in transmitter-specific markers include forebrain cho-linergic systems and noradrenergic and somatostatinergic systems that innervate the telencephalon.

Evaluation of the NINCDS-ADRDA criteria in the differentiation of Alzheimer’s disease and frontotemporal dementia

NINCDS-ADRDA criteria fail accurately to differentiate AD from FTD, and suggestions to improve the diagnostic specificity of the current criteria are made.